Tenax Therapeutics expands levosimendan license to exclusive worldwide oral rights; gains manufacturing rights

TENAX THERAPEUTICS, INC.

Amendment with Orion grants Tenax exclusive worldwide rights to develop, commercialize, and manufacture oral levosimendan products.
Tenax also obtains manufacturing rights for subcutaneously administered levosimendan products under the expanded license.
Orion will supply levosimendan API at low triple-digit thousand Euros/kg, minimum order [***] grams, payment within 45 days.
Fifth Amendment builds on prior agreements; effective September 3, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.